ClinicalTrials.gg
RecruitingNCT07478302Updated May 1, 2026

A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma

A Phase 1 interventional study of SHR-2524 Injection and Bevacizumab Injection in Advanced Unresectable Hepatocellular Carcinoma, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Carcinoma, Hepatocellular by Jiangsu HengRui Medicine Co., Ltd. — 5 open to participants now, 7 under way, 4 of them phase 3. Carcinoma, Hepatocellular · Jiangsu HengRui Medicine Co., Ltd..

Planned enrollment
12th of 13
36 · median 251
Started
2026
with 2 others
Phase 1
Only one
of the 13
Registered
11th of 13
by date

Among the 13 studies in Carcinoma, Hepatocellular by Jiangsu HengRui Medicine Co., Ltd., this one is the 12th largest by planned enrollment, is one of 3 that started in 2026, is the only one in phase 1, and was the 11th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

5 of the 13 studies in Carcinoma, Hepatocellular by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Carcinoma, Hepatocellular by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

This study was a multicenter, open-label phase I clinical trial. This trial will include 36 patients with advanced unresectable hepatocellular carcinoma. Blood samples were obtained during the course of treatment to measure the relative parameter. All Investigational Medicinal Products (IMP) were discontinued after the total cycle.

03

Conditions studied

  • Advanced Unresectable Hepatocellular Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥ 18 years old;
  2. Advanced hepatocellular carcinoma (HCC) confirmed by histopathology or cytology or clinical diagnosis;
  3. The Barcelona clinical liver cancer stage was B or C;
  4. Has not previously received systemic antitumor therapy for HCC;
  5. At least one according to v1.1 criteria;
  6. score of A or B7 ;
  7. score 0 -1;
  8. The expected survival time was ≥12 weeks;
  9. The major organs functioned well;
  10. Has signed the form.

Exclusion criteria

Exclusion Criteria:

  1. Hepatobiliary cell carcinoma, mixed hepatocellular carcinoma-cholangiocarcinoma, sarcomatoid hepatocellular carcinoma, and fibrolamellar hepatocellular carcinoma confirmed by histology or cytology;
  2. Patients with active malignant tumors other than HCC within 5 years or at the same time; Localized tumors that had been cured, such as skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, prostate cancer in situ, cervical cancer in situ, and breast cancer in situ, could be enrolled;
  3. Previous allogeneic organ transplantation (e.g., liver transplantation);
  4. The current liver tumor burden is greater than 50% of the total liver volume;
  5. grade 3 bleeding had occurred within 6 months or CTCAE grade 2 nongastrointestinal bleeding had occurred within 3 months before the first dose;
  6. Abdominal fistula, gastrointestinal perforation, or abdominal abscess within 6 months before the first dose;
  7. Major vascular disease had occurred within 6 months before the first dose;
  8. Current concomitant interstitial pneumonia or interstitial lung disease, or a previous history of interstitial pneumonia or interstitial lung disease requiring hormone therapy;
  9. Innate or acquired immune deficiency (such as infection);
  10. Severe infection occurred within 28 days before the first dose.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    SHR-2524 plus bevacizumab group

    SHR-2524 plus bevacizumab combined with other drugs.

    Drug: SHR-2524 Injection · Drug: Bevacizumab Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Trough serum concentrations (C21d)

    Pharmacokinetics (PK) parameters.

    Time frame: 0 - 21 days.

  2. Area under curve from Day 0 to Day 21 (AUC0-21d)

    Pharmacokinetics (PK) parameters.

    Time frame: 0 - 12 days.

  3. Area under curve up to 21 weeks (AUC0-21weeks)

    Pharmacokinetics (PK) parameters.

    Time frame: 0 - 12 weeks.

Secondary outcomes

  1. Maximum blood concentration (Cmax)

    Pharmacokinetics (PK) parameters.

    Time frame: About 9 months.

  2. Time to peak concentration (Tmax)

    Pharmacokinetics (PK) parameters.

    Time frame: About 9 months.

  3. Area under curve - Time curve from Time 0 to the last quantifiable time point (AUC0-t)

    Pharmacokinetics (PK) parameters.

    Time frame: About 9 months.

  4. Area under curve - Time curve from Time 0 to Infinity (AUC0-∞)

    Pharmacokinetics (PK) parameters.

    Time frame: About 9 months.

  5. Elimination half-life (t1/2)

    Pharmacokinetics (PK) parameters.

    Time frame: About 9 months.

  6. Rate of clearance (CL/F)

    Pharmacokinetics (PK) parameters.

    Time frame: About 9 months.

  7. Geometric mean of the apparent volume of distribution of the population (Vz/F)

    Pharmacokinetics (PK) parameters.

    Time frame: About 9 months.

  8. The number and percentage of anti-drug antibody (ADA) positive participants

    Immunogenicity parameter.

    Time frame: About 9 months.

  9. Adverse events (AEs)

    Safety parameters: The type, incidence, grade (according to the National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI-CTCAE\] v6.0), severity and correlation with Investigational Medicinal Products (IMP) of adverse events (AEs).

    Time frame: About 9 months.

  10. Serious adverse events (SAEs)

    Safety parameters: The type, incidence, grade (according to the National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI-CTCAE\] v6.0), severity and correlation with Investigational Medicinal Products (IMP) of serious adverse events (SAEs).

    Time frame: About 9 months.

  11. Investigator - assessed objective response rate (ORR) based on RECIST v1.1

    Efficacy parameters.

    Time frame: About 9 months.

  12. Investigator - assessed duration of response (DoR) based on RECIST v1.1

    Efficacy parameters.

    Time frame: About 9 months.

  13. Investigator - assessed disease control rate (DCR) based on RECIST v1.1

    Efficacy parameters.

    Time frame: About 9 months.

  14. Investigator - assessed progression-free survival (PFS) based on RECIST v1.1

    Efficacy parameters.

    Time frame: About 9 months.

  15. Investigator - assessed overall survival (OS) based on RECIST v1.1

    Efficacy parameters.

    Time frame: About 9 months.

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Oct 2027, 18 months after the start.

Of 103 industry-sponsored phase 1 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's planned 18 months is below that.

Counting every sponsor, half of 249 studies reached it within 49 months; a quarter within 32 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2026
First posted
Mar 17, 2026
StartActual
Apr 14, 2026
Primary completionEst.
Oct 2027
CompletionEst.
Dec 2027
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07478302
Responsible party
Sponsor
First posted
Mar 17, 2026
Start date
Apr 14, 2026
Primary completion
Oct 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
May 1, 2026

Study contacts

Yang Wu
Contact
yang.wu.yw96@hengrui.com
+86-0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion